REFERENCES
1. Bellera CL, Llanos M, Gantner ME, et al. Can drug repurposing strategies be the solution to the COVID-19 crisis? Expert Opin Drug Discov 2021;16:605-12.
3. Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis 2017;12:64.
4. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 2020;28:165-73.
5. Southall NT, Natarajan M, Lau LPL, et al. IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis 2019;14:225.
6. Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 2019;18:1-2.
7. Begley CG, Ashton M, Baell J, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med 2021;13:eabd5524.
8. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18:41-58.
9. Member States, National Competent Authorities; EU Innovation Offices. Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing. Available from: https://ec.europa.eu/health/system/files/2021-10/pharm773_repurposing_annex_en_0.pdf [Last accessed on 11 Apr 2023].
10. Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J Rare Dis 2018;13:183.
11. U.S. Food and Drug Administration. Search orphan drug designations and approvals. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ [Last accessed on 11 Apr 2023].
12. Orphanet Inserm US14. Lists of medicinal products for rare diseases in Europe. Available from: https://www.myobase.org/doc_num.php?explnum_id=10705 [Last accessed on 11 Apr 2023].
13. Postema PG, Schwartz PJ, Arbelo E, et al. Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. Eur Heart J 2020;41:614-7.
14. Simoens S, Picavet E, Cassiman D, Dooms M. PHP15 What price do we pay for repurposing medicines for rare diseases? Value in Health 2012;15:A15-6.
15. WHO/EURO. Repurposing of medicines in oncology - the underrated champion of sustainable innovation. Available from: https://apps.who.int/iris/bitstream/handle/10665/342567/WHO-EURO-2021-2807-42565-59178-eng.pdf?sequence=1&isAllowed=y [Last accessed on 11 Apr 2023].
16. Aartsma-Rus A, Vroom E, O’Reilly D. The role of patient involvement when developing therapies. Nucleic Acid Ther 2022;32:118-22.
17. Cavaller-Bellaubi M, Faulkner SD, Teixeira B, et al. Sustaining meaningful patient engagement across the lifecycle of medicines: a roadmap for action. Ther Innov Regul Sci 2021;55:936-53.
18. Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci 2015;49:929-39.
19. REPO4EU. The Euro-global platform for mechanism-based drug repurposing. Available from: https://repo4.eu/ [Last accessed on 11 Apr 2023].
20. REMEDi4ALL. The European Platform for medicines repurposing. Available from: https://remedi4all.org/ [Last accessed on 11 Apr 2023].
21. European Commission. Horizon Europe work programme 2021-2022. Available from: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-4-health_horizon-2021-2022_en.pdf [Last accessed on 11 Apr 2023].
22. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Guidance for industry applications covered by section 505(b)(2). Available from: https://www.fda.gov/media/72419/download [Last accessed on 11 Apr 2023].
23. Hechtelt Jonker A, Hivert V, Gabaldo M, et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat Rev Drug Discov 2020;19:495-6.
24. IRDIRC. Drug Repurposing guidebook. Available from: https://irdirc.org/drug-repurposing-guidebook/ [Last accessed on 11 Apr 2023].
25. Asker-Hagelberg C, Boran T, Bouygues C, et al. Repurposing of medicines in the EU: launch of a pilot framework. Front Med (Lausanne) 2021;8:817663.
26. Hivert V, Jonker AH, O’connor D, Ardigo D. IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward strategic actions. Rare Dis Orphan Drugs J 2022;1:3.
27. National Institute of Allergy and Infectious Diseases (NIAID). NOT-AI-16-052: Notice of NIAID’s participation in PA-16-183 “limited competition: Rare Diseases Clinical Research Network (RDCRN) Project supplements for clinical trials to repurpose drugs in collaboration with e-rare awardees (Admin Supp)”. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-052.html [Last accessed on 11 Apr 2023].
28. National Center for Advancing Translational Sciences (NCATS); 0. NOT-TR-19-029: NCATS announces the cures acceleration network review board workshop: repurposing off-patent drugs: research & regulatory challenges. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-029.html [Last accessed on 11 Apr 2023].
29. ERA-LEARN. E-Rare 3 call for proposals 2016 (JTC 2016): clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases. Available from: https://www.era-learn.eu/network-information/networks/e-rare-3/e-rare-3-call-for-proposals-2016-jtc-2016-clinical-research-for-new-therapeutic-uses-of-already-existing-molecules-repurposing-in-rare-diseases [Last accessed on 11 Apr 2023].
30. European Medicines Agency. Clinical trials regulation. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-regulation [Last accessed on 11 Apr 2023].
31. PARADIGM. Patient engagement toolbox. Available from: https://imi-paradigm.eu/petoolbox/ [Last accessed on 11 Apr 2023].
32. U.S. Food Drug Administration. Repurposing off-patent drugs: research & regulatory challenges. Available from: https://www.fda.gov/drugs/news-events-human-drugs/repurposing-patent-drugs-research-regulatory-challenges-12052019-12062019 [Last accessed on 11 Apr 2023].
33. Reagan-Udall Foundation for the FDA. Repurposing off-patent drugs: research & regulatory challenges. Available from: https://reaganudall.salsalabs.org/repurposingoffpatentdrugsworkshop/index.html [Last accessed on 11 Apr 2023].
34. European Medicines Agency. Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia. Available from: https://www.ema.europa.eu/en/news/repurposing-authorised-medicines-pilot-support-not-profit-organisations-academia [Last accessed on 11 Apr 2023].
35. IRDiRC. Shared molecular etiologies underlying multiple rare diseases. Available from: https://irdirc.org/shared-molecular-etiologies/ [Last accessed on 11 Apr 2023].
36. IRDiRC. Pluto Project. Disregarded rare diseases. Available from: https://irdirc.org/pluto-project-disregarded-rare-diseases/ [Last accessed on 11 Apr 2023].
37. IRDiRC. Vision & goals. Available from: https://irdirc.org/about-us/vision-goals/ [Last accessed on 11 Apr 2023].
